Skip to content
Insider tapeFilings through Fri, Oct 2
Watchlist
GILD

Gilead Sciences insider trading

Health Care · Heavy selling
Close · Oct 5, 2026 $144.63 +30.5% over 12 months

Share price and insider trades

GILD closeInsider buyInsider sale
100120140160NovDecJan 2026FebMarAprMayJunJulAugSepOctSold $356,671 on 2025-11-26 · Kelly A. KramerSold $617,500 on 2026-01-20 · Jeffrey BluestoneSold $649,440 on 2025-10-15 · Andrew D Dickinson, Johanna MercierSold $725,078 on 2026-08-20 · Jeffrey BluestoneSold $732,000 on 2025-12-15 · Andrew D Dickinson, Johanna MercierSold $745,860 on 2026-01-15 · Andrew D Dickinson, Johanna MercierSold $747,962 on 2026-06-15 · Andrew D Dickinson, Johanna MercierSold $779,534 on 2026-07-15 · Andrew D Dickinson, Johanna MercierSold $845,760 on 2026-04-15 · Andrew D Dickinson, Johanna MercierSold $865,380 on 2026-03-16 · Andrew D Dickinson, Johanna MercierSold $868,516 on 2026-09-15 · Andrew D Dickinson, Johanna MercierSold $1,193,926 on 2025-10-28 · Daniel Patrick O'daySold $1,248,272 on 2025-12-29 · Daniel Patrick O'daySold $1,291,608 on 2026-04-28 · Daniel Patrick O'daySold $1,368,162 on 2026-03-27 · Daniel Patrick O'daySold $1,398,911 on 2026-01-28 · Daniel Patrick O'daySold $1,447,859 on 2026-02-27 · Daniel Patrick O'daySold $1,894,400 on 2026-07-01 · Daniel Patrick O'daySold $1,954,694 on 2026-08-03 · Daniel Patrick O'daySold $1,971,847 on 2026-06-01 · Daniel Patrick O'daySold $2,218,508 on 2026-10-01 · Daniel Patrick O'daySold $2,229,592 on 2026-09-01 · Daniel Patrick O'daySold $2,247,359 on 2025-11-28 · Daniel Patrick O'day, Jeffrey Bluestone, Kelly A. KramerSold $2,675,220 on 2026-08-26 · Anthony WeltersSold $3,837,248 on 2025-11-17 · Andrew D Dickinson, Johanna MercierSold $4,073,009 on 2026-05-15 · Andrew D Dickinson, Johanna MercierSold $4,268,988 on 2026-08-17 · Andrew D Dickinson, Johanna MercierSold $4,787,518 on 2026-02-17 · Andrew D Dickinson, Johanna MercierSold $6,590,487 on 2025-11-12 · Deborah H TelmanSold $15,611,400 on 2026-01-23 · Daniel Patrick O'daySold $17,346,000 on 2026-02-05 · Daniel Patrick O'day
Bought, 12 months$0
Sold, 12 months$87.6M
Insiders buying0
Insiders selling7

Valuation, profit and volume

P/E (trailing)n/aSector median 24.5
Market value— 
Profit margin—Revenue growth —
Volume vs. 50-day0.9×Last 5 sessions
Insiders' paper profit—On all tracked purchases —

Summary

Over the past 12 months, 0 Gilead Sciences insiders reported open-market purchases totaling $0, while 7 insiders reported sales totaling $87.6M. 78 of 79 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.

Insider transactions

Open-market purchases and sales. 84 grants, option exercises and tax withholdings are not shown.

Filed Insider Type Shares Price Value Since Score
Oct 2SEC Daniel Patrick O'dayCEO, Chair Sell Plan 12,000 $147.72 $1.8M -2.1% —
Oct 2SEC Daniel Patrick O'dayCEO, Chair Sell Plan 3,000 $148.63 $446K -2.7% —
Sep 16SEC Andrew D DickinsonCFO Sell Plan 3,000 $145.29 $436K -0.5% —
Sep 16SEC Johanna MercierChief Comm & Corp Aff Officer Sell Plan 1,600 $143.69 $230K +0.7% —
Sep 16SEC Johanna MercierChief Comm & Corp Aff Officer Sell Plan 800 $144.46 $116K +0.1% —
Sep 16SEC Johanna MercierChief Comm & Corp Aff Officer Sell Plan 600 $145.29 $87K -0.5% —
Sep 2SEC Daniel Patrick O'dayCEO, Chair Sell Plan 7,992 $148.36 $1.2M -2.5% —
Sep 2SEC Daniel Patrick O'dayCEO, Chair Sell Plan 5,408 $149.38 $808K -3.2% —
Sep 2SEC Daniel Patrick O'dayCEO, Chair Sell Plan 1,600 $147.51 $236K -2.0% —
Aug 27SEC Anthony WeltersDirector Sell Plan 6,880 $148.82 $1.0M -2.8% —
Aug 27SEC Anthony WeltersDirector Sell Plan 4,600 $148.82 $685K -2.8% —
Aug 27SEC Anthony WeltersDirector Sell Plan 3,402 $148.24 $504K -2.4% —
Aug 27SEC Anthony WeltersDirector Sell Plan 3,118 $148.31 $462K -2.5% —
Aug 21SEC Jeffrey BluestoneDirector Sell Plan 1,816 $144.92 $263K -0.2% —
Aug 21SEC Jeffrey BluestoneDirector Sell Plan 1,658 $145.73 $242K -0.8% —
Aug 21SEC Jeffrey BluestoneDirector Sell Plan 1,165 $143.75 $167K +0.6% —
Aug 21SEC Jeffrey BluestoneDirector Sell Plan 335 $146.26 $49K -1.1% —
Aug 21SEC Jeffrey BluestoneDirector Sell Plan 26 $146.36 $4K -1.2% —
Aug 18SEC Johanna MercierChief Comm & Corp Aff Officer Sell Plan 16,530 $137.37 $2.3M +5.3% —
Aug 18SEC Johanna MercierChief Comm & Corp Aff Officer Sell Plan 11,470 $138.04 $1.6M +4.8% —
Aug 18SEC Andrew D DickinsonCFO Sell Plan 3,000 $138.36 $415K +4.5% —
Aug 4SEC Daniel Patrick O'dayCEO, Chair Sell Plan 7,700 $130.80 $1.0M +10.6% —
Aug 4SEC Daniel Patrick O'dayCEO, Chair Sell Plan 6,700 $129.66 $869K +11.5% —
Aug 4SEC Daniel Patrick O'dayCEO, Chair Sell Plan 600 $131.34 $79K +10.1% —
Jul 16SEC Andrew D DickinsonCFO Sell Plan 3,000 $129.93 $390K +11.3% —
Jul 16SEC Johanna MercierChief Comm & Corp Aff Officer Sell Plan 3,000 $129.92 $390K +11.3% —
Jul 2SEC Daniel Patrick O'dayCEO, Chair Sell Plan 11,900 $126.09 $1.5M +14.7% —
Jul 2SEC Daniel Patrick O'dayCEO, Chair Sell Plan 3,100 $127.08 $394K +13.8% —
Jun 16SEC Andrew D DickinsonCFO Sell Plan 3,000 $125.40 $376K +15.3% —
Jun 16SEC Johanna MercierChief Comm & Corp Aff Officer Sell Plan 1,480 $123.42 $183K +17.2% —
Jun 16SEC Johanna MercierChief Comm & Corp Aff Officer Sell Plan 1,070 $124.00 $133K +16.6% —
Jun 16SEC Johanna MercierChief Comm & Corp Aff Officer Sell Plan 450 $125.40 $56K +15.3% —
Jun 2SEC Daniel Patrick O'dayCEO, Chair Sell Plan 10,900 $131.10 $1.4M +10.3% —
Jun 2SEC Daniel Patrick O'dayCEO, Chair Sell Plan 3,062 $132.22 $405K +9.4% —
Jun 2SEC Daniel Patrick O'dayCEO, Chair Sell Plan 1,038 $132.97 $138K +8.8% —
May 18SEC Johanna MercierChief Comm & Corp Aff Officer Sell Plan 11,177 $131.19 $1.5M +10.2% —
May 18SEC Johanna MercierChief Comm & Corp Aff Officer Sell Plan 8,374 $132.23 $1.1M +9.4% —
May 18SEC Johanna MercierChief Comm & Corp Aff Officer Sell Plan 7,749 $130.29 $1.0M +11.0% —
May 18SEC Andrew D DickinsonCFO Sell Plan 3,000 $132.27 $397K +9.3% —
May 18SEC Johanna MercierChief Comm & Corp Aff Officer Sell Plan 700 $132.75 $93K +8.9% —
Apr 29SEC Daniel Patrick O'dayCEO, Chair Sell Plan 6,950 $128.79 $895K +12.3% —
Apr 29SEC Daniel Patrick O'dayCEO, Chair Sell Plan 3,050 $130.01 $397K +11.2% —
Apr 16SEC Andrew D DickinsonCFO Sell Plan 3,000 $140.96 $423K +2.6% —
Apr 16SEC Johanna MercierChief Comm & Corp Aff Officer Sell Plan 3,000 $140.96 $423K +2.6% —
Mar 30SEC Daniel Patrick O'dayCEO, Chair Sell Plan 10,000 $136.82 $1.4M +5.7% —
Mar 17SEC Andrew D DickinsonCFO Sell Plan 3,000 $144.23 $433K +0.3% —
Mar 17SEC Johanna MercierChief Comm & Corp Aff Officer Sell Plan 3,000 $144.23 $433K +0.3% —
Mar 2SEC Daniel Patrick O'dayCEO, Chair Sell Plan 6,419 $145.18 $932K -0.4% —
Mar 2SEC Daniel Patrick O'dayCEO, Chair Sell Plan 3,481 $144.04 $501K +0.4% —
Mar 2SEC Daniel Patrick O'dayCEO, Chair Sell Plan 100 $145.71 $15K -0.7% —
Feb 18SEC Johanna MercierChief Comm & Corp Aff Officer Sell Plan 18,405 $154.18 $2.8M -6.2% —
Feb 18SEC Johanna MercierChief Comm & Corp Aff Officer Sell Plan 9,395 $154.91 $1.5M -6.6% —
Feb 18SEC Andrew D DickinsonCFO Sell Plan 3,000 $154.43 $463K -6.3% —
Feb 18SEC Johanna MercierChief Comm & Corp Aff Officer Sell Plan 200 $155.62 $31K -7.1% —
Feb 6SEC Daniel Patrick O'dayCEO, Chair Sell Plan 115,640 $150.00 $17.3M -3.6% —
Jan 29SEC Daniel Patrick O'dayCEO, Chair Sell Plan 5,032 $139.54 $702K +3.6% —
Jan 29SEC Daniel Patrick O'dayCEO, Chair Sell Plan 4,968 $140.24 $697K +3.1% —
Jan 26SEC Daniel Patrick O'dayCEO, Chair Sell Plan 115,640 $135.00 $15.6M +7.1% —
Jan 21SEC Jeffrey BluestoneDirector Sell Plan 5,000 $123.50 $618K +17.1% —
Jan 16SEC Andrew D DickinsonCFO Sell Plan 3,000 $124.31 $373K +16.3% —
Jan 16SEC Johanna MercierChief Commercial Officer Sell Plan 3,000 $124.31 $373K +16.3% —
Dec 30SEC Daniel Patrick O'dayCEO, Chair Sell Plan 10,000 $124.83 $1.2M +15.9% —
Dec 16SEC Andrew D DickinsonCFO Sell Plan 3,000 $122.00 $366K +18.5% —
Dec 16SEC Johanna MercierChief Commercial Officer Sell Plan 3,000 $122.00 $366K +18.5% —
Dec 1SEC Daniel Patrick O'dayCEO, Chair Sell Plan 6,788 $126.84 $861K +14.0% —
Dec 1SEC Jeffrey BluestoneDirector Sell 5,000 $125.08 $625K +15.6% —
Dec 1SEC Daniel Patrick O'dayCEO, Chair Sell Plan 3,212 $125.91 $404K +14.9% —
Dec 1SEC Kelly A. KramerDirector Sell Plan 2,806 $127.11 $357K +13.8% —
Dec 1SEC Kelly A. KramerDirector Sell Plan 2,805 $127.10 $357K +13.8% —
Nov 18SEC Johanna MercierChief Commercial Officer Sell Plan 25,524 $125.83 $3.2M +14.9% —
Nov 18SEC Andrew D DickinsonCFO Sell Plan 2,500 $125.23 $313K +15.5% —
Nov 18SEC Johanna MercierChief Commercial Officer Sell Plan 2,476 $126.26 $313K +14.6% —
Nov 13SEC Deborah H TelmanEvp, Corporate Affairs & Gc Sell Plan 35,965 $122.30 $4.4M +18.3% —
Nov 13SEC Deborah H TelmanEvp, Corporate Affairs & Gc Sell Plan 17,181 $124.00 $2.1M +16.6% —
Nov 13SEC Deborah H TelmanEvp, Corporate Affairs & Gc Sell Plan 500 $122.90 $61K +17.7% —
Oct 29SEC Daniel Patrick O'dayCEO, Chair Sell Plan 7,978 $119.54 $954K +21.0% —
Oct 29SEC Daniel Patrick O'dayCEO, Chair Sell Plan 2,022 $118.82 $240K +21.7% —
Oct 16SEC Johanna MercierChief Commercial Officer Sell Plan 3,000 $118.08 $354K +22.5% —
Oct 16SEC Andrew D DickinsonCFO Sell Plan 2,500 $118.08 $295K +22.5% —

Insiders at Gilead Sciences

InsiderBoughtSoldLast filingScore
Daniel Patrick O'dayCEO, Chair — $52.4M Oct 2, 2026 —
Johanna MercierChief Comm & Corp Aff Officer — $18.5M Sep 16, 2026 —
Deborah H TelmanEvp, Corporate Affairs & Gc — $6.6M Nov 13, 2025 —
Andrew D DickinsonCFO — $4.7M Sep 16, 2026 —
Anthony WeltersDirector — $2.7M Aug 27, 2026 —
Jeffrey BluestoneDirector — $2.0M Aug 21, 2026 —
Kelly A. KramerDirector — $713K Dec 1, 2025 —
Erin BurkhartSvp, Controllership — — Sep 23, 2026 —
Wettan Keeley M CainEvp Gen Counsel, Legal & Comp — — Sep 11, 2026 —
Dietmar BergerChief Medical Officer — — Sep 11, 2026 —
Harish ManwaniDirector — — May 4, 2026 —
Jacqueline K BartonDirector — — May 4, 2026 —
Ted W LoveDirector — — May 4, 2026 —
Javier RodriguezDirector — — May 4, 2026 —
Sandra HorningDirector — — May 4, 2026 —

Insider activity at other Health Care companies

Same sector, ranked by insider buying in the last 90 days.

  • BSXBoston Scientific$9.5M bought
  • PFEPfizer$3.0M bought
  • COOCooper Companies (The)$1.9M bought
  • ELVElevance Health$1.4M bought
  • PODDInsulet Corporation$162K bought
  • SYKStryker Corporation$27K bought

Common questions about GILD insiders

Are Gilead Sciences insiders buying GILD stock?

In the past 12 months, 0 insiders reported open-market purchases of GILD worth $0.

Are Gilead Sciences insiders selling GILD stock?

7 insiders reported sales worth $87.6M over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.